Vivos Therapeutics, Inc. (VVOS): Entry into a Material Definitive Agreement
Vivos Therapeutics, Inc. (VVOS) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. false 0001716166 0001716166 2026-06-25 2026-06-25 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Repor
How this was made
The 30-second read
Why it matters
The June 18, 2026 Letter Agreement amends the Exchange Agreement by extending the outside date to complete a qualifying financing of at least $2.6 million from June 15, 2026 to Aug. 31, 2026, and is disclosed via a June 25, 2026 8-K.
Market read
This is a liquidity/timing update for a minimum $2.6M qualifying financing, which can shift near-term risk perception and trading around microcap financing expectations.
What to watch
Traders should watch for details of the qualifying financing terms (size, pricing, and whether preferred/common conversion mechanics increase dilution) and any subsequent amendments before the new outside date.
Background
Vivos Therapeutics previously agreed with Streeterville Capital to exchange a portion of its indebtedness for preferred and common stock under an Exchange Agreement dated June 5, 2026.
Ticker impact
Vivos Therapeutics entered a letter agreement with Streeterville Capital to extend the outside date for a $2.6M qualifying financing to Aug. 31, 2026.
Likely modest relief bid on deadline extension; follow-through depends on whether the $2.6M financing is completed by Aug. 31.
The filing is a fresh 8-K disclosure of a contractual deadline extension tied to a minimum $2.6M financing, which can affect perceived liquidity risk and timing of potential equity issuance.
Market effects
Adds to the broader microcap biotech financing/dilution narrative, but no sector-wide regulatory or clinical catalyst is disclosed.
No specific regional market linkage beyond US-listed microcap risk sentiment.
Limited; the disclosure is company-specific and not tied to global regulatory or supply-chain events.
Counterpoint
A deadline extension can signal difficulty securing the qualifying financing, so the stock may still face renewed selling pressure as Aug. 31 approaches.
Key entities
- public_companyVivos Therapeutics, Inc.
NASDAQ-listed company (VVOS) disclosing the amended financing deadline in an 8-K.
- counterpartyStreeterville Capital, LLC
Counterparty that agreed to amend the Exchange Agreement and extend the qualifying financing outside date.
